Lucid Capital Markets Starts Avalo Therapeutics Inc. (AVTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
BTIG Starts Avalo Therapeutics Inc. (AVTX) at Buy
December 19, 2024 6:05 AM ESTBTIG analyst Julian Harrison initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $40.00.
The analyst comments "We see AVTXs IL-1 mAb AVTX-009 having best-inclass features that could support preferred positioning in several large I&I indications. Lead efforts are in hidradenitis suppurativa, where we continue to expect significant reward for more active Tx options, even after key... More
